Sodium Iodide (I-123) Curium Netherlands

Sodium Iodide (123 I) is a radiopharmaceutical used for diagnostic imaging of thyroid function and structure. It emits gamma radiation for imaging while minimizing patient radiation exposure. This EU-sourced product is administered intravenously for nuclear medicine procedures. Ideal for thyroid scans and uptake studies.

Sodium Iodide (123 I) is primarily used in nuclear medicine for diagnostic imaging of the thyroid gland. It helps evaluate thyroid function, detect nodules, and assess post-surgical thyroid tissue. The radiopharmaceutical is also used in whole-body scans to identify metastatic thyroid cancer. It provides clear imaging with low radiation dose for accurate diagnosis.

After intravenous administration, Sodium Iodide (123 I) is absorbed by the thyroid gland, where it emits gamma rays detectable by imaging equipment. The radiation is localized to the thyroid, minimizing exposure to other tissues. Patients may experience mild discomfort at the injection site, but systemic effects are rare. Imaging typically occurs within hours, providing timely diagnostic results.

Sodium Iodide (123 I) should be handled by trained medical professionals in controlled environments. Pregnant or breastfeeding patients should avoid this product due to radiation exposure risks. Patients with known iodine sensitivity or thyroid disorders may require special consideration. Always follow radiation safety protocols during administration and disposal.

Concurrent use of thyroid medications, such as levothyroxine, may interfere with Sodium Iodide (123 I) uptake and imaging results. Iodine-containing contrast agents or supplements can also affect diagnostic accuracy. Alcohol and certain foods may alter thyroid function temporarily. Always inform your healthcare provider about all medications and supplements before administration.